论文部分内容阅读
为了阐明临床应用造血干细胞动员剂硫酸葡聚糖(DS)的可能性,用不同动物进行了动员效果、LD_(50)过敏实验和正常人体试用研究。结果表明,给狗静脉注射分子量为10kDa的DS后,血中MNC和CFU-GM呈时相性变化,1h开始增加,5h达到高峰值;LD_(50)为1128.6mg/kg(雄性小鼠)和1369.4mg/kg(雌性小鼠),两者之间无显著差异;分子量为10kDa的DS过敏反应为阴性结果,15kDa的DS为阳性结果;34例正常人体试用,DS可使血中CFU-GM、BFU-E和CFU-GEMM,分别增加到给药前的8倍、10.5倍和12倍,有效、安全剂量约为15～20mg/kg。分子量为10kDa的DS人体试用研究属国内外首次报道。
In order to elucidate the possibility of clinical application of hematopoietic stem cell mobilizing agent dextran sulfate (DS), mobilization effects, LD50 allergy tests and normal human trials were performed with different animals. The results showed that the MNC and CFU-GM in the blood changed in a time-dependent manner after intravenous injection of DS with a molecular weight of 10 kDa, increasing at 1 h and reaching a peak at 5 h. The LD 50 was 1128.6 mg / kg (male mice) and 1369.4mg / kg (female mice), no significant difference between the two; molecular weight 10kDa DS allergic reaction was negative results, 15kDa DS positive results; 34 normal human trial, DS can make blood CFU-GM , BFU-E and CFU-GEMM increased to 8 times, 10.5 times and 12 times before administration, respectively. The effective and safe dose was about 15 ~ 20mg / kg. DS molecular weight of 10kDa human trial is the first report at home and abroad.